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   Squamous  cell  carcinoma  (SCC)  of  the  oropharynx  affects  nearly  50,000  
individuals  in  the  United  States  each  year,  and,  with  the  rising  incidence  of  the  
human  papillomavirus  (HPV),  the  number  of  patients  diagnosed  with  SCC  is  
expected  to  continue  to  grow  (American  Cancer  Society  2018;;  Coughlan  and  
Frick  2012).  Oropharyngeal  squamous  cell  carcinoma  (OPSCC)  has  traditionally  
been  treated  with  wide  surgical  extirpation  often  involving  removal  of  portions  of  
the  oral  cavity,  pharynx,  and  jaw;;  this  kind  of  surgery  can  be  disfiguring  and  has  
been  associated  with  significant  post-­operative  complications  (Brickman  and  
Gross  2014).  In  the  late  20th  century,  clinicians  began  favoring  the  use  of  
chemoradiation  therapy  instead  of  surgery  in  an  effort  to  spare  patients  the  
morbidity  associated  with  surgical  techniques  at  the  time  (Mercante  et  al.  2015).  
While  chemoradiation  offers  excellent  survival  for  patients  with  SCC,  this  
therapeutic  strategy  has  been  observed  to  have  its  own  debilitating  post-­
treatment  side  effects  (Hamilton  and  Paleri  2017).  An  important  advancement  in  
the  management  of  OPSCC  occurred  about  20  years  ago  with  the  advent  of  
transoral  robotic  surgery  (TORS),  a  surgical  technique  that  uses  a  robotic  system  
	  	   v 
to  operate  through  the  natural  opening  of  the  mouth.  Proponents  of  TORS  
suggest  that  the  technology  improves  on  conventional  surgery  and  may  provide  
patients  with  functional  outcomes  superior  to  those  seen  with  chemoradiation  
with  no  sacrifice  in  survival  (Yeh  et  al.  2015;;  Hay  et  al.  2017).  This  review  
investigates  the  validity  of  the  concept  that  TORS  has  significant  advantages  in  
the  modern-­day  treatment  of  OPSCC.  This  report  includes  three  components.  
First,  the  TORS  technology,  its  advantages,  and  its  drawbacks  are  explained.  
Second,  relevant  medical  literature  is  reviewed  to  provide  an  understanding  of  
the  rationale  for  utilizing  TORS  in  the  treatment  of  OPSCC.  Review  and  analysis  
of  published  reports  show  that  TORS  can  provide  patients  with  excellent  post-­
operative  function,  good  quality  of  life,  and  acceptable  survival  rates.  Notable  
exceptions  include  patients  with  advanced  disease.  Third,  this  review  discusses  
future  studies  that  will  better  inform  caregivers  about  the  utility  of  TORS  in  the  
treatment  of  OPSCC.  TORS  is  a  relatively  new  technology  that  seems  to  offer  
the  possibility  of  helping  to  improve  the  lives  of  patients  with  OPSCC.    
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INTRODUCTION  
 
UNDERSTANDING  OROPHARYNGEAL  CANCER  
Oropharyngeal  squamous  cell  carcinoma  (OPSCC)  is  cancer  that  arises  from  the  
tissue  that  lines  the  middle  region  of  the  throat.  The  oropharynx,  where  this  
cancer  appears,  sits  posterior  to  the  oral  cavity  and  is  surrounded  by  the  
nasopharynx  superiorly  and  by  the  hypopharynx  inferiorly  (Hermans  2011).  The  
major  anatomical  features  of  the  oropharynx  are  the  palatine  tonsils,  the  tonsillar  
pillars,  the  base  of  the  tongue,  the  ventral  surface  of  the  soft  palate  and  the  
uvula,  the  posterior  and  lateral  pharyngeal  walls,  and  the  glossotonsillar  sulcus  
(Li,  Agrawal,  and  Fakhry  2015;;  Moore  2015).    
  
The  severity  of  a  given  OPSCC,  also  known  as  its  stage,  is  based  upon  three  
categories:  T,  the  extent  of  the  primary  tumor,  N,  the  involvement  of  nearby  
lymph  nodes,  and  M,  the  metastasis  of  the  cancer  to  distant  organs.  Once  T,  N,  
and  M  values  have  been  established  for  a  given  carcinoma,  through  surgical  
biopsy  of  the  tumor  tissue  and  clinical  assessment  of  local  and  distant  tissues,  a  
stage  is  assigned  (American  Cancer  Society  2018).  The  most  recent  guidelines  
set  forward  by  the  American  Joint  Committee  on  Cancer  (AJCC)  in  January  2018  
identify  5  stages  for  OPSCC,  zero  through  four,  each  with  increasing  severity  
(American  Cancer  Society  2018).  It  is  important  to  note  that  there  are  different  
staging  schemata  for  human  papillomavirus  (HPV)-­positive  and  HPV-­negative  
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disease,  because,  as  discussed  later  in  this  thesis,  these  distinct  etiologies  are  
associated  with  different  disease  progressions  and  outcomes.    
  
For  HPV-­negative  OPSCC,  stage  zero  disease  includes  all  carcinomas  that  have  
not  spread  beyond  the  epithelium  of  the  oropharynx  (American  Cancer  Society  
2018).  Stage  one  and  two  describe  carcinomas  that  are  becoming  progressively  
more  voluminous  and  have  spread  to  layers  deeper  than  the  epithelium  (T1-­2)  
without  involving  other  organ  systems  (N0,  M0);;  stage  three  describes  
carcinomas  that  are  either  larger  locally  (T3)  or  have  spread  to  one  nearby  lymph  
node  (T1-­3,  N1)  (American  Cancer  Society  2018).  Tumors  with  substantial  local  
growth  (T4),  disease  with  multiple  lymph  nodes  involved  (N2-­3),  and  all  
metastatic  disease  (M1)  are  classified  as  stage  four  (American  Cancer  Society  
2018).  The  most  common  site  of  metastases  from  primary  OPSCC  is  the  lungs  
for  both  HPV-­positive  and  HPV-­negative  disease  (Huang  et  al.  2013).    
  
Staging  is  similar  for  HPV-­positive  OPSCC,  although  some  additional  disease  
progression  is  included  in  each  stage.  For  instance,  stage  one  HPV-­positive  
OPSCC  includes  tumors  ranging  in  severity  from  T0  to  T2,  and  up  to  one  node  
may  be  involved  (N1)  (American  Cancer  Society  2018).  This  stands  in  contrast  to  
HPV-­negative  disease,  where  a  T2-­graded  tumor  incurs  a  stage  two  designation,  
and  any  nodal  involvement  incurs  a  stage  3  designation  (American  Cancer  
Society  2018).  In  HPV-­positive  OPSCC,  stage  three  encompasses  large  tumors  
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(T3-­4)  with  extensive  nodal  involvement  (N2),  and  stage  four  describes  any  
disease  that  has  metastasized  (American  Cancer  Society  2018).  
  
EPIDEMIOLOGY,  MORTALITY,  AND  ECONOMICS    
OPSCC  is  currently  a  major  public  health  concern.  In  the  United  States,  more  
than  50,000  individuals  are  diagnosed  with  cancer  of  the  oral  cavity  or  pharynx  
each  year,  and  the  vast  majority  of  these  cases  are  squamous  cell  carcinoma  
(American  Cancer  Society  2018;;  Johnson  and  Amarasinghe  2011).  In  a  given  
year,  these  same  malignancies  claim  approximately  10,000  lives  (American  
Cancer  Society  2018).  The  chances  of  surviving  cancer  of  the  oral  cavity  or  
pharynx  start  off  fairly  high,  but  drop  precipitously  as  the  disease  becomes  more  
advanced.  The  rates  of  patient  survival  five  years  following  treatment  in  2013  in  
the  United  States  were  83.7%  for  those  with  locally-­confined  cancer,  64.2%  for  
those  with  disease  involving  regional  lymph  nodes,  and  38.5%  for  those  with  
distantly  metastatic  disease  (SEER  Cancer  Statistics  Review  2014).  This  trend  in  
mortality  becomes  particularly  concerning  when  it  is  considered  in  conjunction  
with  the  fact  that  many  patients  with  pharyngeal  cancer  seek  medical  care  only  
once  their  disease  has  reached  an  advanced  stage  (Worsham  2011).  
Additionally,  while  rates  of  mortality  due  to  oral  cavity  and  pharyngeal  cancers  
have  traditionally  been  declining,  this  improvement  has  recently  languished  
(American  Cancer  Society  2018).    
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The  major  risk  factors  for  developing  OPSCC  have  traditionally  been  tobacco  
and  alcohol  consumption  (Leibowitz  and  Civantos  2013).  More  recently,  as  will  
be  discussed  later  in  this  paper,  HPV  has  also  demonstrated  a  prominent  role  in  
the  etiology  of  OPSCC  (Leibowitz  and  Civantos  2013).  As  this  virus  has  spread,  
so  too  has  the  incidence  of  OPSCC.  It  has  been  estimated  that  since  the  turn  of  
the  21st  century,  the  incidence  of  OPSCC  has  increased  5%  yearly  (Coughlan  
and  Frick  2012).    
  
Head  and  neck  cancer,  the  disease  category  that  includes  OPSCC,  is  
burdensome  for  the  patients  it  afflicts.  These  cancers  are  known  to  behave  
aggressively,  destroying  structures  near  the  primary  tumor  and  often  spreading  
quickly  to  lymph  nodes  and  distant  organs  (Johnson  and  Amarasinghe  2011).  
OPSCC  and  other  head  and  neck  cancers  are  also  burdensome  on  the  
healthcare  system  and  economy.  In  2003,  as  the  HPV-­related-­OPSCC  epidemic  
was  in  its  early  years,  Ekwueme  et  al.  estimated  that  oral  and  pharyngeal  
cancers  cost  more  than  $1.37  billion  in  productivity  lost  to  disease-­related  
mortality  (Ekwueme  et  al.  2008).  Given  the  burden  OPSCC  places  on  patients  
and  society  and  the  rising  incidence  of  this  disease,  it  is  clear  that  further  
research  and  innovation  in  OPSCC  treatment  are  warranted.  
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UNDERSTANDING  ONCOLOGIC  OUTCOMES    
Researchers  and  clinicians  use  a  number  of  parameters  to  evaluate  the  
effectiveness  of  a  given  cancer  treatment.  Much  of  this  review  hinges  on  
understanding  these  parameters  to  compare  treatment  options.  Therefore,  the  
major  parameters  will  be  briefly  reviewed  below.    
  
In  the  study  of  OPSCC  treatment,  two  anatomical  parameters  are  widely  
considered:  local  control  (LC),  referring  to  the  anatomical  site  of  the  primary  
tumor,  and  regional  control  (RC),  referring  to  nearby  lymph  nodes  (Psychogios  et  
al.  2014).  LC  and  RC  can  be  given  as  a  duration  of  time,  such  as  the  time  
following  initial  treatment  before  cancer  returns  in  the  location  or  region  of  the  
primary  tumor,  or  as  a  rate,  such  as  the  percentage  of  patients  in  a  study  cohort  
that  do  not  have  a  cancer  recur  locally  or  regionally  in  a  predetermined  period  of  
time  (Psychogios  et  al.  2014;;  Ling  et  al.  2016).  Some  studies  combine  LC  and  
RC  into  the  parameter  locoregional  control  (LRC).  Many  studies  also  consider  
overall  survival  (OS),  the  time  measured  from  cancer  diagnosis  or  treatment  
initiation  for  which  an  affected  individual  is  still  alive,  and  disease-­free  or  relapse-­
free  survival  (DFS,  RFS),  the  time  from  treatment  completion  where  a  patient  is  
free  of  disease  (National  Cancer  Institute  n.d.).  While  these  parameters  are  
defined  in  lengths  of  time,  their  respective  rates  can  also  be  compared.  A  
commonly  considered  rate  is  the  disease-­specific  survival  rate,  which  is  defined  
as  the  percentage  of  a  patient  group  that  has  not  died  from  one  particular  
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disease  in  a  given  time  frame  (National  Cancer  Institute  n.d.).  Failure  rates,  the  
inverse  counterparts  of  the  aforementioned  parameters,  are  also  sometimes  
mentioned;;  for  instance,  the  regional  failure  rate  is  the  percentage  of  a  patient  
cohort  where  regional  recurrence  is  seen,  or  conversely,  where  regional  control  
is  not  seen  (Ling  et  al.  2016).    
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HISTORY  OF  OPSCC  TREATMENT  
 
THE  OPEN  SURGERY  ERA  
In  the  late  20th  century,  the  common  practice  for  management  of  oropharyngeal  
cancers  was  surgery  preceded  or  followed  by  radiation  (Parsons  et  al.  1992).  
The  widespread  use  of  combination  strategies  as  opposed  to  treatment  with  
either  surgery  or  radiation  alone  was  likely  a  result  of  studies  showing  superior  
oncologic  outcomes  with  combination  treatment.  For  example,  in  a  1990  
retrospective  review  of  115  patients  treated  for  cancer  of  the  tongue  base  
between  1974  and  1984,  Weber  and  colleagues  demonstrated  a  24%  
improvement  in  local  control  rate  over  radiation  alone  with  combination  surgery  
and  radiation  (55%  versus  79%)  (Weber  et  al.  1990).    
  
However,  the  oncologic  superiority  of  combination  surgery  with  radiation  was  not  
definitive  from  an  empirical  standpoint  at  this  time;;  indeed,  a  prospective,  
randomized  trial  published  by  the  Radiation  Therapy  Oncology  Group  (RTOG)  in  
1987  showed  no  statistically  significant  differences  in  4-­year  overall  survival  or  
locoregional  control  for  patients  treated  for  OPSCC  with  either  radiation  alone  or  
radiation  in  combination  with  surgical  resection  (Kramer  et  al.  1987).  
Nonetheless,  the  combination  of  surgery  with  radiation  predominated  the  
treatment  of  patients  in  this  time  period.  In  a  retrospective  review  of  16,188  
patients  treated  for  squamous  cell  carcinoma  of  the  tongue  base  from  1985  to  
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1996,  Zhen  and  colleagues  determined  that  the  most  common  treatment  
strategy,  used  in  more  than  a  quarter  (26.9%)  of  these  patients,  was  combination  
surgery  with  radiation  (Zhen  et  al.  2004).    
  
Conventional  surgery  for  OPSCC  at  the  turn  of  the  21st  century,  while  purported  
to  offer  tumor  control  and  survival  benefits  for  patients,  was  not  without  
significant  shortcomings.  Before  the  advent  of  robotic  surgery,  accessing  tumors  
of  the  posterior  oropharynx,  including  the  base  of  the  tongue,  was  a  surgical  
challenge.  An  approach  through  the  oral  cavity  was  difficult  with  conventional  
instruments,  and  surgeons  were  generally  required  to  split  the  jawbone  
(mandibulectomy  or  mandibulotomy)  or  approach  the  region  of  interest  through  
the  neck  musculature  (pharyngotomy)  (Brickman  and  Gross  2014).  Indeed  at  the  
time,  the  open  surgical  strategies  seemed  to  offer  superior  oncologic  control  
when  compared  with  attempts  to  resect  tumors  transorally  due  to  the  difficulty  of  
achieving  complete  tumor  resection  when  operating  through  the  mouth  (Whicker,  
Desanto,  and  Devine  1974).  Open  procedures  were  invasive  and  often  damaged  
important,  functional  bone  and  soft  tissue.  For  instance,  Dziegielewski  and  
colleagues  reported  on  the  use  of  the  lip-­splitting  mandibulotomy,  a  technique  
involving  a  midline  incision  through  the  lower  lip  and  subsequent  splitting  of  the  
mandible,  to  treat  220  patients  with  upper  aerodigestive  cancers  (74%  
oropharyngeal  squamous  cell  carcinoma)  between  1998  and  2006  (Dziegielewski  
et  al.  2009).  22  of  these  patients  (10%)  encountered  complications  after  surgery,  
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the  most  prevalent  of  which  were  issues  with  healing  such  as  orocutaneous  
fistulae  and  other  cosmetic  defects  (Dziegielewski  et  al.  2009).  A  subsequent  
study  produced  by  the  University  of  Maryland  reported  complication  rates  of  over  
40%  with  this  surgical  approach  (Dyalram-­Silverberg  et  al.  2011).  The  use  of  
pharyngotomy  to  access  the  oropharynx,  either  with  a  lateral  approach  as  
depicted  in  Figure  1  or  through  or  around  the  hyoid  bone  (transhyoid  
pharyngotomy  and  suprahyoid  pharyngotomy,  respectively)  has  been  associated  
with  similarly  high  complication  rates  of  up  to  38%  (Brickman  and  Gross  2014).  
Notable  complications  of  this  procedure  included  severe  swallowing  impairment  




Figure  1.  The  lateral  pharyngotomy.  Accessing  the  oropharynx  surgically  has  
traditionally  required  splitting  external  neck  and  throat  musculature  as  well  as  the  
mandible.  These  so-­called  “open”  approaches  are  invasive  and  often  debilitating  
for  patients.  Figure  taken  from  (Laccourreye  et  al.  2013)  via  Wiley  Online  Library.    
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THE  CHEMORADIATION  ERA    
A  seminal  study  published  in  1991  by  the  Veterans  Affairs  Laryngeal  Cancer  
Study  Group  (VALCSG)  marked  the  start  of  new  era  in  the  treatment  of  head  and  
neck  cancer  (Kelly  et  al.  2014).  Prior  to  the  publication  of  this  study,  the  standard  
for  treatment  in  laryngeal  cancer,  much  like  to  the  treatment  of  oropharyngeal  
cancer,  was  surgery  (laryngectomy)  with  or  without  postoperative  radiation  
(Department  of  Veterans  Affairs  Laryngeal  Cancer  Study  Group  et  al.  1991).  Like  
the  open  surgical  approaches  for  oropharyngeal  cancer,  surgical  management  of  
laryngeal  cancer  was  associated  with  significant,  life-­altering  morbidity.  Due  to  
tissue  removal  and  damage,  patients  treated  with  laryngectomy  have  permanent  
voice  alterations:  some  become  completely  aphonic  while  others  learn  to  speak  
with  their  esophagus  or  with  a  mechanical  aid  (McNeil,  Weichselbaum,  and  
Pauker  1981).  Many  develop  serious  complications  with  swallowing  and  
gustation  (McNeil,  Weichselbaum,  and  Pauker  1981).  These  complications  
prompted  physicians  to  seek  alternative  treatment  strategies  that  could  maintain  
favorable  oncologic  outcomes  while  delivering  improved  functional  outcomes  for  
patients.  These  are  often  referred  to  as  “organ  preservation”  strategies  (Kelly  et  
al.  2014).    
  
The  VALCSG  study  involved  randomizing  332  patients  to  two  treatment  groups:  
one  receiving  chemotherapy  and  radiation  and  the  other  receiving  surgery  with  
postoperative  radiation  (Department  of  Veterans  Affairs  Laryngeal  Cancer  Study  
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Group  et  al.  1991).  The  researchers  found  that  the  larynx  was  spared  in  64%  of  
the  chemoradiation  group  (as  opposed  to  0%  in  the  surgical  group)  without  
compromising  the  survival  rate  at  two  years  after  treatment  (Department  of  
Veterans  Affairs  Laryngeal  Cancer  Study  Group  et  al.  1991).  By  demonstrating  
through  a  prospective  model  that  functional  outcomes  of  laryngeal  cancer  
treatment  could  be  improved  without  significantly  sacrificing  oncologic  control,  
the  results  of  this  study  strongly  supported  organ  preservation  through  non-­
surgical  methods.    
  
Following  the  publication  of  the  VALCSG  study,  the  focus  on  organ  preservation  
made  its  way  into  the  treatment  of  oropharyngeal  malignancies  (Dabas  et  al.  
2017;;  Turner,  Byrd,  and  Ferris  2016).  Emerging  evidence  at  the  time  suggested  
that  radiation  therapy  offered  excellent  oncologic  control  while  avoiding  the  
functional  complications  often  seen  with  open  surgical  approaches.  In  1994,  
Hinerman  and  colleagues  published  a  retrospective  review  of  134  patients  
treated  with  either  external  beam  radiation  or  surgical  resection  (Hinerman  et  al.  
1994).  Excellent  5-­year  local  control  rates  of  90%  for  T1  oropharyngeal  
malignancies,  92%  for  T2,  and  73%  for  T3  were  reported,  suggesting  that  
radiation  monotherapy  was  a  viable  alternative  to  primary  surgery  (Hinerman  et  
al.  1994).  A  2002  study  by  Parsons  et  al.  further  bolstered  the  case  for  deferring  
open  surgery.  The  investigators  analyzed  the  management  of  over  6000  patients  
treated  for  tongue  base  and  tonsillar  cancers  at  academic  institutions  in  the  
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United  States  and  Canada  between  1970  and  2000,  specifically  comparing  the  
use  of  primary  open  surgery  (with  or  without  postoperative  radiation)  with  primary  
radiation  (with  or  without  adjuvant  neck  dissection)  (Parsons  et  al.  2002).  For  
both  the  tongue  base  and  tonsillar  cancer  groups,  no  significant  differences  in  
local  control,  locoregional  control,  5-­year  overall  survival,  or  5-­year  disease-­
specific  survival  were  observed  between  the  two  treatment  modalities  (Parsons  
et  al.  2002).  However,  notable  differences  in  the  incidence  of  severe  
complications  were  observed.  32%  of  patients  treated  with  primary  surgery  for  
tongue  base  malignancies  encountered  complications,  as  did  23%  of  patients  
treated  with  surgery  for  tonsillar  malignancies;;  their  radiation  counterparts  had  
much  lower  complication  rates  of  3.8%  (tongue  base)  and  6.0%  (tonsil)  (Parsons  
et  al.  2002).  Taken  together,  the  results  of  this  study  strongly  supported  the  
paradigm  shift  from  open  surgery  toward  radiation  for  oropharyngeal  cancers.        
  
Treatment  for  oropharyngeal  cancers  was  subsequently  escalated  to  include  
chemotherapy  in  addition  to  radiation  after  a  number  of  studies  showed  the  
improved  oncologic  outcomes  of  the  two  treatments  in  combination  (Turner,  
Byrd,  and  Ferris  2016).  Calais  et  al.  conducted  a  prospective  trial  that  
randomized  226  patients  to  receive  either  radiation  monotherapy  or  radiation  with  
concomitant  chemotherapy  with  carboplatin  and  5-­fluorouracil  (Calais  et  al.  
1999).  In  1999,  the  team  published  results  showing  a  statistically  significant  
increase  in  overall  survival  over  the  radiation  group  for  the  group  treated  with  
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combination  chemoradiation  (Calais  et  al.  1999).  Additionally,  rates  of  local  
control  were  higher  for  the  combination  group:  66%,  versus  42%  for  the  
monotherapy  group  (Calais  et  al.  1999).  The  incremental  oncologic  control  
offered  by  the  addition  of  concomitant  chemotherapy  was  also  demonstrated  by  
the  Groupe  d’Etude  des  Tumeurs  de  la  Tête  Et  du  Cou  (GETTEC).  When  
compared  with  a  control  group  of  patients  receiving  surgery  with  adjuvant  
radiation  or  radiation  alone,  a  group  treated  with  combination  chemoradiation  
showed  a  significantly  improved  overall  survival  rate  (Domenge  et  al.  2000).    
  
A  recent  meta-­analysis  of  studies  published  between  1965  and  2000  summarizes  
the  empirical  thought  regarding  the  treatment  of  squamous  cell  carcinoma  of  the  
head  and  neck  near  the  turn  of  the  21st  century.  Pignon  et  al.  reviewed  87  trials  
encompassing  16,485  patients  and  concluded  that  the  addition  of  chemotherapy  
to  local  control  efforts  (surgery  +/-­  radiation  or  radiation  alone)  was  associated  
with  a  significant  increase  in  overall  survival  (Pignon  et  al.  2009).  On  this  
empirical  foundation,  a  decline  in  the  use  of  open  surgery  was  seen  in  the  early  
21st  century,  as  the  paradigm  shifted  toward  non-­surgical,  organ-­preserving  
strategies  (Haigentz  et  al.  2009).    
  
While  evidence  suggested  superior  oncologic  outcomes  with  chemoradiation  as  
opposed  to  surgery  or  radiation  alone,  researchers  quickly  noted  the  drawbacks  
of  this  treatment  strategy  (Dabas  et  al.  2017).  Radiation  therapy  for  head  and  
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neck  cancer  has  been  shown  to  be  strongly  associated  with  severe  mucositis,  as  
over  60%  of  patient  subjected  to  this  treatment  develop  grade-­three-­or-­worse  
mucositis  and  the  accompanying  pain,  difficulty  eating,  and  reduced  quality  of  life  
(Trotti  2000;;  Trotti  et  al.  2003).  Some  patients  with  severe  mucositis  additionally  
require  hospitalizations,  intensive  care,  and/or  feeding  support  (Trotti  et  al.  2003).  
Furthermore,  the  escalation  of  radiation  regimens  with  concomitant  
chemotherapy  has  been  shown  to  worsen  functional  side  effects.  The  
aforementioned  study  by  Calais  et  al.  (1999)  showed  a  significant  increase  in  the  
incidence  of  severe  mucositis  in  the  group  treated  with  chemoradiation  over  the  
group  treated  with  radiation  alone  (Calais  et  al.  1999).  Meta-­analyses  have  also  
contributed  to  the  scientific  community’s  understanding  of  the  toxicities  
associated  with  concurrent  chemoradiation;;  for  instance,  J.  M.  Henk  reviewed  19  
prospective  chemoradiation  trials  and  concluded  that  the  addition  of  
chemotherapy  to  radiotherapy  regimens  for  the  treatment  of  head  and  neck  
cancers  significantly  worsens  functional  outcomes  for  patients  (Henk  1997).  
Severe  dysphagia,  the  need  for  permanent  gastrostomy  tube  placement,  and  
tracheostomy  have  also  been  widely  reported  as  side  effects  of  chemoradiation  
used  to  treat  oropharyngeal  cancers  (Rosenthal  et  al.  2014;;  Levendag  et  al.  
2007).    
  
The  functional  burden  of  chemoradiation  regimens  used  to  treat  OPSCC  has  
become  even  more  clear  in  recent  years  through  both  retrospective  and  
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prospective  trials.  Machtay  et  al.  retrospectively  analyzed  three  studies  
previously  conducted  by  the  RTOG  and  found  that  35%  of  patients  treated  with  
chemoradiation  for  OPSCC  developed  severe  toxicities  (Machtay  et  al.  2008).  
The  toxicities  analyzed  were  significant  and  quality-­of-­life-­lowering;;  for  instance,  
12.6%  of  the  cohort  experienced  feeding  tube  dependence  more  than  two  years  
after  treatment  (Machtay  et  al.  2008).  A  prospective  study  conducted  by  Givens  
et  al.  observed  mucositis  and  hematologic  toxicities  in  more  than  half  of  the  104  
patients  treated  with  concomitant  chemoradiation  for  head  and  neck  cancer  (72  
of  whom  had  OPSCC)  (Givens  et  al.  2009).  Furthermore,  this  group  observed  
gastrostomy  tube  dependence  at  the  1-­year  post-­treatment  mark  in  more  than  
26%  of  the  cohort,  and  tracheostomy  dependence  in  almost  14%  (Givens  et  al.  
2009).  
  
As  the  scientific  community’s  understanding  of  chemoradiation  side  effects  
developed,  novel  treatment  options  promising  fewer  side  effects  began  to  
emerge.  Intensity-­modulated  radiation  therapy  (IMRT)  came  to  the  forefront  in  
the  early  21st  century  as  an  alternative  to  conventional  external  beam  radiation  
(Nutting,  Dearnaley,  and  Webb  2000).  By  using  improved  three-­dimensional  
software  modeling,  IMRT  purports  to  offer  adequate  radiation  delivery  to  tumor  
tissue  while  minimizing  irradiation  of  healthy,  surrounding  tissue  (Nutting,  
Dearnaley,  and  Webb  2000).  In  theory,  IMRT  could  provide  similar  oncologic  
control  as  traditional  radiation  while  reducing  toxicities  and  the  resultant  
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functional  deficits  (de  Arruda  et  al.  2006).  Early  studies  investigating  the  use  of  
IMRT  in  nasopharyngeal  carcinomas  showed  promising  results.  Lee  et  al.  
demonstrated  with  67  patients  that  excellent  locoregional  control  could  be  
achieved  with  IMRT  plus  concurrent  chemotherapy  for  early-­stage  
nasopharyngeal  carcinomas  (Lee  et  al.  2002).  Promisingly,  large  reductions  in  
mucositis,  xerostomia,  and  other  common  side-­effects  were  seen  with  the  IMRT  
regimen  compared  to  conventional  radiation  (Lee  et  al.  2002).    
  
The  application  of  IMRT  in  OPSCC  treatment  showed  similarly  promising  results.  
In  2006,  de  Arruda  et  al.  retrospectively  evaluated  50  patients  treated  with  IMRT  
(86%  with  concurrent  chemotherapy)  for  oropharyngeal  malignancies  ranging  
from  T1  to  T4  (de  Arruda  et  al.  2006).  For  the  entire  cohort,  the  local  control  rate,  
regional  control  rate,  metastatic  control  rate,  and  overall  survival  rate  at  2  years  
were  98%,  88%,  84%,  and  98%  (de  Arruda  et  al.  2006).  Huang  et  al.  reported  a  
similarly  encouraging  3-­year  locoregional  control  of  90%  for  71  patients  with  
advanced-­stage  oropharyngeal  cancer  treated  with  IMRT  (Huang  et  al.  2008).  In  
both  of  these  studies,  limiting  the  dose  of  radiation  delivered  to  healthy  
structures,  namely  the  parotid  glands,  yielded  improved  functional  outcomes  over  
conventional  radiation  (de  Arruda  et  al.  2006;;  Huang  et  al.  2008).  However,  
treatment  with  IMRT  was  not  without  notable  side  effects.  In  the  de  Arruda  et  al.  
study,  38%  of  patients  developed  severe  mucositis,  and  Huang  et  al.  observed  
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33%  of  patients  with  at  least  moderate-­grade  mucositis  (de  Arruda  et  al.  2006;;  
Huang  et  al.  2008).    
  
Rosenthal  et  al.  highlighted  the  importance  of  understanding  the  side  effects  
associated  with  chemoradiation  even  in  the  age  of  advanced  radiation  
techniques.  Of  the  149  head  and  neck  cancer  patients  surveyed  by  this  group  
(47%  of  whom  had  oropharyngeal  cancer),  more  than  half  reported  significant  
(defined  as  greater  than  or  equal  to  5  on  a  10-­point  scale)  issues  with  swallowing  
and  gustation  up  to  7  weeks  after  treatment  completion  (Rosenthal  et  al.  2014).  
Pain,  fatigue,  and  dry  mouth  were  among  the  other  commonly-­reported  long-­
lasting  side  effects  (Rosenthal  et  al.  2014).    
  
Given  the  serious  side  effects  of  radiation  and  combination  chemoradiation,  there  
has  been  a  rising  interest  in  optimizing  treatment  modalities  to  reduce  patients’  
functional  deficits  following  treatment  (Yeh  et  al.  2015).    
  
HPV  AND  THE  DE-­ESCALATION  ARGUMENT  
Many  of  the  aforementioned  studies,  upon  which  the  paradigm  of  treating  
OPSCC  with  chemoradiation  was  built  in  the  late  20th  and  early  21st  centuries,  
focused  on  providing  curative  treatment  to  patients  with  advanced-­stage  disease  
(Deschler  et  al.  2014;;  Chai  et  al.  2015).  The  vast  majority  of  these  cases  were  
related  to  tobacco  and  alcohol  use  and  appeared  in  older  individuals  (Applebaum  
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et  al.  2007;;  Deschler  et  al.  2014).  However,  following  the  turn  of  the  21st  century,  
the  demographic  presenting  with  new  cases  of  OPSCC  began  to  change.  An  
increasing  proportion  of  younger  individuals  under  the  age  of  60  without  
significant  histories  of  tobacco  or  alcohol  abuse  were  being  diagnosed  with  
oropharyngeal  malignancies  (Taberna  et  al.  2017).  The  smoking  rate  in  the  
United  States  declined  from  40%  in  1965  to  around  20%  in  2010,  and  a  resultant  
decrease  in  the  incidence  of  oral,  laryngeal,  and  hypopharyngeal  cancers  was  
seen  (Pytynia,  Dahlstrom,  and  Sturgis  2014;;  Centers  for  Disease  Control  and  
Prevention  2010).  Incidence  rates  of  oropharyngeal  cancer  fell  similarly  between  
1973  and  2003  (Johnson  and  Amarasinghe  2011).  However,  this  decrease  in  
oropharyngeal  cancer  incidence  was  transient.  As  depicted  in  Figure  2,  rates  of  




Figure  2:  Incidences  of  head  and  neck  cancers  by  year.  It  is  important  to  note  
the  uptick  in  cancers  of  the  pharynx  and  tongue  around  the  turn  of  the  21st  
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century.  The  increased  incidence  in  these  categories  was  likely  related  to  the  
HPV  virus.  Figure  taken  from  (Sturgis  and  Cinciripini  2007)  via  Wiley  Online  
Library.  
  
The  incidence  of  oropharyngeal  cancer  has  continued  to  increase  in  the  21st  
century,  recently  reaching  epidemic  levels.  In  recent  years,  there  has  been  a  
51%  increase  in  oropharyngeal  cancers  while  the  incidence  of  other  head  and  
neck  malignancies  continues  to  decrease  in  the  Western  world  (Hamilton  and  
Paleri  2017).  The  increasingly  concerning  rise  in  the  incidence  of  oropharyngeal  
malignancies  despite  falling  smoking  rates  is  now  known  to  be  due  to  the  human  
papillomavirus  (HPV).  In  2011,  it  was  reported  that  nearly  60%  of  new  
oropharyngeal  cancers  were  HPV-­related,  compared  to  around  40%  prior  to  
2000  (Posner  et  al.  2011;;  Moore  and  Mehta  2015).  HPV-­associated  head  and  
neck  cancers  now  represent  a  significant  public  health  problem  (Coughlan  and  
Frick  2012).  This  problem  can  almost  entirely  be  attributed  to  OPSCC,  as  HPV  is  
not  known  to  cause  cancers  in  other  regions  of  the  head  and  neck  (Centers  for  
Disease  Control  and  Prevention  2018).  
  
HPV  is  a  family  of  over  100  closely-­related  viruses  that  are  transmitted  primarily  
through  sexual  contact  (World  Health  Organization  2016).  In  fact,  HPV  is  the  
most  widespread  sexually  transmitted  infection  in  the  world  (Milner  2015).  The  
carcinogenic  properties  of  certain  strains  of  HPV  became  clear  in  the  latter  half  of  
the  20th  century  as  research  emerged  showing  the  presence  of  HPV  DNA  in  
many  cervical  and  ano-­genital  cancers  (IARC  Working  Group  on  the  Evaluation  
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of  Carcinogenic  Risks  to  Humans  and  International  Agency  for  Research  on  
Cancer  2007).  Today,  it  is  known  that  at  least  13  strains  of  HPV  are  cancer-­
causing;;  these  are  called  “high  risk”  infections  (World  Health  Organization  2016).  
One  particular  strain  of  HPV,  HPV-­16,  has  proven  to  be  particularly  widespread  
in  cancers;;  indeed,  a  causal  link  between  infection  with  this  strain  and  cervical  
cancer  was  demonstrated  in  1992  (Munoz  et  al.  1992).  Early  evidence  for  the  
role  of  HPV-­16  infection  in  oropharyngeal  cancers  emerged  in  1990  when  in  situ  
hybridization  of  a  cohort  of  tonsillar  cancers  revealed  HPV-­16  DNA  (Niedobitek  et  
al.  1990).  Subsequent  research  showed  that  the  presence  of  HPV  in  the  oral  
cavity  and  throat  was  significantly  associated  with  the  development  of  
oropharyngeal  cancer,  independent  of  patient  alcohol  or  tobacco  use  (Smith  et  
al.  1998).  The  role  of  HPV-­16  in  head  and  neck  cancer  was  further  elucidated  
through  a  retrospective  review  of  259  patients  treated  for  OPSCC  between  1987  
and  1998  (Gillison  et  al.  2000).  HPV  infection  was  discovered  in  25%  of  these  
cases,  with  HPV-­16  specifically  making  up  90%  of  HPV-­positive  tumors  (Gillison  
et  al.  2000).    
  
To  understand  how  HPV-­16  causes  cancerous  changes  of  human  soft  tissue,  it  
is  necessary  to  understand  the  behavior  of  this  viral  family  and  the  structure  of  
this  strain.  Papillomaviruses  preferentially  infect  the  basal  layers  of  stratified  
epithelia  (IARC  Working  Group  on  the  Evaluation  of  Carcinogenic  Risks  to  
Humans  and  International  Agency  for  Research  on  Cancer  2007).  In  a  non-­
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pathological  scenario,  basal  epithelial  cells  replicate  and  subsequently  move  into  
more  superficial  layers  of  the  skin,  arresting  their  cell  cycle;;  however,  in  the  case  
of  HPV  infection,  HPV-­positive  basal  cells  do  not  stop  proliferating  after  migrating  
from  the  basal  layer  (IARC  Working  Group  on  the  Evaluation  of  Carcinogenic  
Risks  to  Humans  and  International  Agency  for  Research  on  Cancer  2007).  The  
HPV-­16  genome  encodes  a  number  of  proteins  that,  when  expressed  by  human  
host  cells  following  infection,  cause  a  transition  to  the  pathologic  scenario  defined  
above  (Taberna  et  al.  2017).    
  
Research  in  cervical  cancer  has  revealed  that  the  E6  and  E7  proteins  encoded  
by  the  HPV  genome  are  particularly  important  in  disrupting  the  normal  cell  cycle  
in  epithelial  cells  (Rampias  et  al.  2009).  Building  upon  this  knowledge,  Rampais  
et  al.  (2009)  demonstrated  that  the  E6  and  E7  oncoproteins  expressed  by  HPV-­
16-­positive  human  oropharyngeal  cells  are  necessary  to  cause  malignant,  hyper-­
proliferative  changes  in  these  cells  (Rampias  et  al.  2009).  It  is  now  understood  
that  the  oncogenic  properties  of  E6  and  E7  proteins  derive  from  the  proteins’  
abilities  to  inhibit  the  vital  tumor  suppressor  proteins  p53  and  pRb,  respectively  
(Rampias  et  al.  2009).  Inhibition  of  these  tumor  suppressors  leads  to  the  
accumulation  of  genetic  mutations  in  oropharyngeal  cells  and  a  consequent  
transition  to  malignancy  (Mirghani  et  al.  2015).  Indeed,  Ferris  et  al.  (2005)  
demonstrated  that  repression  of  E6  expression  in  a  cell  line  derived  from  OPSCC  
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of  the  tongue  base  resulted  in  restoration  of  p53  tumor  suppressor  function  
(Ferris  et  al.  2005).      
  
Understanding  the  role  of  HPV  infection  in  OPSCC  is  important  for  a  number  of  
reasons.  First  and  foremost,  the  rise  of  HPV-­associated  malignancies  in  the  head  
and  neck  to  epidemic  rates  warrants  increased  research  in  order  to  properly  care  
the  ever-­increasing  number  of  afflicted  individuals.  Additionally,  given  that  HPV-­
related  OPSCC  has  been  shown  to  be  caused  by  virally-­encoded  oncoproteins  
that  are  not  present  in  HPV-­negative  tissue,  it  can  be  inferred  that  HPV-­positive  
tumor  tissue  may  respond  differently  to  treatment  and  may  be  amenable  to  
different  treatment  strategies  (Licitra  et  al.  2006).  
  
In  accordance  with  this  idea,  many  recent  studies  have  demonstrated  more  
favorable  responses  to  treatment  for  patients  with  HPV-­positive  oropharyngeal  
tumors  over  HPV-­negative  individuals.  A  meta-­analysis  conducted  by  Ragin  and  
Taioli  reviewed  37  studies  published  prior  to  2007  and  concluded  that  patients  
with  HPV-­positive  squamous  cell  carcinoma  of  the  head  and  neck  have  higher  
rates  of  overall  survival  and  lower  rates  of  local  tumor  recurrence  after  treatment  
compared  to  their  HPV-­negative  counterparts  (Ragin  and  Taioli  2007).  Ang  et  al.  
subsequently  showed  that  tumor  HPV  status  is  a  valid  and  independent  predictor  
of  patient  survival  (Ang  et  al.  2010).  Taken  together  with  the  excellent  survival  
and  local  control  rates  seen  for  OPSCC  treatment,  the  results  reported  by  Ragin  
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and  Taioli  and  Ang  et  al.  suggest  that  there  may  be  a  degree  of  overtreatment  in  
the  HPV-­positive  OPSCC  population  (de  Arruda  et  al.  2006;;  Huang  et  al.  2008;;  
Kelly,  Husain,  and  Burtness  2016).    
  
With  this  in  mind,  it  is  important  consider  the  demographic  presenting  with  HPV-­
induced  OPSCC.  As  previously  mentioned,  these  individuals  tend  to  be  younger  
than  traditional,  HPV-­negative  OPSCC  patients  (Deschler  et  al.  2014).  As  a  
result,  significant  functional  impairment  following  treatment  in  these  patients  will  
lead  to  many  years  of  poor  quality  of  life  (Mirghani  et  al.  2015).  Understanding  
this  sobering  fact  and  also  that  patients  with  HPV-­positive  OPSCC  may  respond  
more  favorably  to  treatment  has  prompted  a  recent  interest  in  de-­intensifying  the  
standard  treatment  for  this  population  (Hamilton  and  Paleri  2017).  
  
THE  REEMERGENCE  OF  SURGERY  
Advances  in  surgical  procedures,  particularly  the  introduction  of  transoral  robotic  
surgery  (TORS),  have  added  potentially  revolutionary  strategies  to  the  treatment  
options  for  OPSCC.  By  offering  a  minimally-­invasive  approach  to  oropharyngeal  
tumors,  TORS  improves  upon  conventional,  open  surgical  methods  and  reduces  
postoperative  morbidity  (Park  et  al.  2013).  Additionally,  by  using  surgery  as  the  
primary  treatment  modality,  TORS  may  help  patients  avoid  the  severe  toxicities  
associated  with  radiation  and  combination  chemoradiation  (Park  et  al.  2013).  The  
potential  upsides  of  TORS  have  stimulated  research  into  the  viability  of  the  
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technique  in  both  the  widespread  treatment  of  OPSCC  and  the  de-­intensification  
of  treatment  for  patients  with  HPV-­positive  tumors.  This  review,  as  outlined  in  the  
Specific  Aims,  will  explore  this  viability.    
     




This  review  aims  to  accomplish  the  following  goals:  
1.   Provide  an  understanding  of  transoral  robotic  surgery  technology  as  well  
as  its  advantages  and  drawbacks  
2.   Review  literature  published  to  date  to  explore  the  functional,  quality  of  life,  
and  oncologic  outcomes  of  TORS  in  the  treatment  of  OPSCC,  particularly  
when  compared  to  non-­surgical  treatment  options  
3.   Discuss  related  ongoing  research  and  how  it  will  influence  the  role  of  
TORS  in  the  future    
     
	   26	  
TORS  AND  THE  MANAGEMENT  OF  OPSCC  
 
INTRODUCTION  TO  ROBOTIC  SURGERY  
Robot-­assisted  surgery  was  pioneered  in  other  surgical  fields,  namely  urologic  
and  cardiac  surgery,  before  its  initial  applications  in  head  and  neck  surgery  
(Smith  and  Herrell  2005;;  Dogan  et  al.  2001).  Surgeons  in  the  former  fields  noted  
improvement  over  conventional  surgical  techniques  with  the  use  of  a  robotic  
system,  with  assisted  surgeries  yielding  lower  complication  rates  and  shorter  
lengths  of  stay  compared  to  conventional  surgeries  (Smith  and  Herrell  2005;;  
Donias  et  al.  2003).    
  
The  improvements  upon  conventional  surgery  are  related  to  the  properties  of  the  
robot.  When  operating  with  a  robotic  system,  the  surgeon  sits  at  a  console  and  
virtually  operates  the  arms  of  the  robot.  The  robotic  arms,  which  are  connected  to  
the  surgical  instruments,  are  able  to  move  with  seven  degrees  of  freedom  
(Hamilton  et  al.  2017).  In  comparison,  the  human  arm,  while  itself  having  7  
degrees  of  freedom  across  the  three  major  joints,  has  only  3  degrees  of  freedom  
at  the  wrist;;  additionally,  when  using  an  endoscope,  the  surgeon’s  arm  is  limited  
to  4  degrees  of  freedom  (de  Almeida  and  Genden  2012).  Furthermore,  one  or  
more  of  the  robotic  arms  can  support  cutting-­edge  stereoscopic  optics,  allowing  
three-­dimensional  visualization  and  up  to  75%  better  resolution  than  a  traditional  
endoscope  (Hockstein,  Nolan,  O’Malley,  et  al.  2005;;  Hamilton  and  Paleri  2017).  
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Finally,  the  robot  is  equipped  with  software  to  scale  the  surgeon’s  input,  
eliminating  natural  tremors  and  potentially  erroneous  movements  (Hamilton  et  al.  
2017).  Together,  these  improvements  allow  minimally-­invasive  approaches  to  
tumors  and  more  delicate  handling  of  tissue  (Hockstein,  Nolan,  O’Malley,  et  al.  
2005).    
  
THE  ADVENT  OF  TRANSORAL  ROBOTIC  SURGERY  
Transoral  robotic  surgery  (TORS),  the  use  of  robotic  systems  to  operate  through  
the  mouth,  was  developed  at  the  University  of  Pennsylvania  in  the  early  2000s  
(O’Malley  et  al.  2006).  In  a  series  of  pre-­clinical  studies  involving  an  airway  
mannequin,  a  canine  model,  and  a  human  cadaver,  Hockstein  et  al.  explored  the  
use  of  a  robotic  system  in  pharyngeal  and  laryngeal  surgeries  (Hockstein,  Nolan,  
O’Malley,  et  al.  2005;;  Hockstein,  Nolan,  O’Malley,  et  al.  2005;;  Weinstein,  
O’Malley,  and  Hockstein  2005).  In  these  preliminary  studies,  the  surgeons  noted  
that  operating  with  a  robotic  system  allowed  increased  precision  and  delicacy  
over  conventional  surgical  instruments  (Hockstein,  Nolan,  O’Malley,  et  al.  2005).  
This  was  a  result  of  the  aforementioned  optical  improvement  over  traditional  
endoscope-­guided  surgery,  increased  freedom  of  instrument  movement,  and  
motion-­scaling  and  tremor-­reducing  software  inherent  in  the  robotic  system  
(Hockstein,  Nolan,  O’Malley,  et  al.  2005;;  Hockstein,  Nolan,  O’malley,  et  al.  2005;;  
Hagen,  Stein,  and  Curet  2014).  An  additional  and  paradigm-­shifting  benefit  of  
using  a  robotic  system  in  pharyngeal  surgery  is  that  the  instruments  can  
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approach  the  surgical  site  through  the  natural  opening  of  the  mouth,  eliminating  
the  need  for  open  approaches  through  the  neck  musculature  and  mandible  that,  
as  described  earlier,  have  been  associated  with  significant  morbidity  (Hockstein,  
Nolan,  O’Malley,  et  al.  2005).    
  
While  TORS  improves  on  conventional  head  and  neck  surgery  in  many  ways,  it,  
too,  has  drawbacks.  The  most  notable  shortcoming  is  cost,  as  each  robotic  
system  costs  more  than  a  million  dollars  (de  Almeida  and  Genden  2012).  
Another  drawback  is  the  tactile  feedback  that  the  surgeon  forgoes  when  
operating  through  a  robot  as  opposed  to  with  his  or  her  own  hands  (de  Almeida  
and  Genden  2012).  Nonetheless,  TORS  emerged  in  the  early  21st  century  as  a  
promising  technology  in  a  field  desperate  for  treatment  innovation.  TORS  was  
approved  by  the  United  States’  Federal  Drug  Administration  (FDA)  in  2009  (de  
Almeida  and  Genden  2012).  Subsequent  studies  have  since  been  designed  to  
further  understand  the  capacity  and  limitations  of  TORS.    
  
EARLY  STUDIES  
After  establishing  the  feasibility  of  robot-­assisted  surgery  of  the  throat  with  
preclinical  models,  the  team  at  the  University  of  Pennsylvania  turned  to  clinical  
studies  to  more  thoroughly  investigate  the  novel  technique  and  its  potential  to  
revolutionize  the  management  of  oropharyngeal  neoplasms.  In  2006,  O’Malley  et  
al.  conducted  the  first  trial  of  TORS  in  human  patients,  using  the  technology  to  
	   29	  
resect  malignancies  of  the  tongue  base  (O’Malley  et  al.  2006).  Three  patients,  
two  with  T2  disease  and  one  with  T1,  underwent  TORS  with  adjuvant  neck  
dissection.  The  first  two  patients  were  operated  upon  with  prophylactic  
tracheostomy,  but  following  encouraging  results  with  these  patients,  including  
limited  throat  swelling  and  rapid  decannulation,  the  third  patient  did  not  have  a  
tracheostomy  tube  placed  (O’Malley  et  al.  2006).  In  each  of  the  three  patients,  
the  surgical  team  was  able  to  remove  the  tumor  in  one  piece,  which  was  a  
distinct  improvement  upon  even  the  most  advanced  surgical  techniques  of  the  
time  (O’Malley  et  al.  2006).  By  removing  the  tumor  whole  rather  than  in  several  
fragments  as  was  required  with  other  surgical  methods,  the  team  was  able  to  
operate  with  deeper,  more  definitive  margins  and  with  less  inadvertent  damage  
to  healthy  surrounding  structures  (O’Malley  et  al.  2006).  No  patient  encountered  
significant  complications  with  the  TORS  procedure  in  this  early  study,  and  all  
patients  were  able  to  tolerate  a  full  oral  diet  within  6  weeks  (O’Malley  et  al.  2006).  
Two  of  the  patients  subsequently  received  chemoradiation  as  planned,  while  the  
third  received  only  adjuvant  radiation  (O’Malley  et  al.  2006).  
  
Following  these  encouraging  results,  the  team  at  the  University  of  Pennsylvania  
next  piloted  the  use  of  TORS  in  patients  with  tonsillar  OPSCC.  In  this  study,  27  
adult  patients  underwent  a  TORS-­mediated  tonsillectomy;;  some  then  received  a  
neck  dissection  and/or  adjuvant  chemoradiation  (Weinstein  et  al.  2007).  One  
patient  failed  to  follow  up  after  treatment,  but  of  the  remaining  26,  no  locoregional  
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disease  recurrence  was  seen  in  the  6-­month  study  window  (Weinstein  et  al.  
2007).  This  was  particularly  striking  given  that  many  of  the  patients  in  the  study  
had  advanced-­stage  disease  (more  than  90%  with  T3-­T4  OPSCC)  (Weinstein  et  
al.  2007).  In  general,  the  complications  associated  with  the  TORS  radical  
tonsillectomy  in  this  study  were  low.  Of  the  cohort,  19%  of  patients  had  acute  
complications  such  as  bleeding,  although  these  universally  resolved  within  6  
months  (Weinstein  et  al.  2007).  Only  one  patient  in  this  cohort  received  an  
unplanned  tracheostomy  (Weinstein  et  al.  2007).  Notably,  no  patients  in  this  
study  encountered  the  severe  complications  regularly  associated  with  non-­
robotic  radical  tonsillectomy  such  as  fistula  development  (Weinstein  et  al.  2007).    
  
An  important  finding  of  this  2007  study  was  that  primary  surgery  with  TORS  
supplied  tissue  for  histopathological  analysis.  This  allowed  for  accurate  
pathological  staging  of  patients  following  surgery  (Weinstein  et  al.  2007;;  de  
Almeida  and  Genden  2012).  Patients’  postoperative  plans  were  adjusted  
according  to  these  pathology  results,  and  almost  half  of  the  patients  in  this  study  
were  able  to  avoid  chemotherapy  (Weinstein  et  al.  2007).  While  these  patients  
still  received  radiation  therapy,  it  can  be  assumed  that  their  treatment  burden  
was  less  than  if  they  had  received  the  addition  of  chemotherapy.  Two  patients  
with  moderately-­advanced  and  advanced  disease  (T2  and  T3  OPSCC)  whose  
tumors  were  removed  with  negative  surgical  margins  (i.e.,  there  was  no  reason  
to  suspect  incomplete  tumor  removal)  received  no  postoperative  chemotherapy  
	   31	  
or  radiation  at  all  (Weinstein  et  al.  2007).  Presumably,  these  patients  avoided  
many  of  the  complications  commonly  associated  with  radiation  of  the  oropharynx  
and  systemic  chemotherapy.    
  
These  seminal  studies  showed  the  feasibility  of  TORS  in  treating  patients  with  
OPSCC.  The  robotic  technology  was  used  to  remove  malignancies  of  the  tongue  
base  and  tonsils  with  precision  and  relatively  low  morbidity,  demonstrating  a  
clear  superiority  over  previously  established  surgical  techniques  (Weinstein  et  al.  
2007).  With  the  evidence  from  these  studies  and  the  notion  that  surgery  could  
reduce  the  need  for  chemoradiation,  the  doors  were  opened  for  researchers  to  
further  explore  the  functional,  quality  of  life,  and  oncologic  outcomes  of  TORS  for  
the  treatment  of  OPSCC.      
  
FUNCTIONAL  OUTCOMES  
Proponents  of  robotic  surgery  in  OPSCC  treatment  champion  the  idea  that  the  
transoral  approach  and  surgical  resection  of  the  tumor  will  afford  patients  
functional  outcomes  superior  to  conventional  surgery,  chemoradiation,  and  
combinations  thereof  (de  Almeida  and  Genden  2012).  Indeed,  the  earliest  
studies  conducted  by  the  team  at  the  University  of  Pennsylvania  showed  
promising  results  with  few  serious  complications  (O’Malley  et  al.  2006;;  Weinstein  
et  al.  2007).  The  obvious  limitations  of  the  studies  conducted  by  O’Malley  et  al.  
and  Weinstein  et  al.  were  the  small  patient  cohorts  (30  patients  between  the  two  
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studies)  and  the  short  duration  of  the  postoperative  follow-­up  periods  (less  than  
or  equal  to  6  months)  (O’Malley  et  al.  2006;;  Weinstein  et  al.  2007).  The  studies  
establishing  the  toxicities  associated  with  chemoradiation,  on  the  other  hand,  had  
observed  the  functional  outcomes  for  thousands  of  patients  over  several  years  
following  treatment  (Machtay  et  al.  2008;;  Givens  et  al.  2009).  
  
Surgeons  following  the  lead  of  the  University  of  Pennsylvania  team  began  using  
the  technology  in  their  own  operating  rooms;;  over  the  coming  years,  the  number  
of  studies  examining  the  functional  outcomes  of  TORS  used  for  OPSCC  
treatment  expanded.    
  
In  2009,  Genden  et.  al  reported  on  their  experience  using  TORS  to  treat  20  
patients  for  OPSCC  at  Mount  Sinai  (Genden,  Desai,  and  Sung  2009).  While  the  
patient  population  was  small,  functional  outcomes  with  respect  to  swallowing  
were  excellent.  The  team  observed  that  every  patient  tolerated  an  oral  diet  
quickly  following  surgery  (1.4  days  on  average),  and  no  patient  required  a  
feeding  tube  (Genden,  Desai,  and  Sung  2009).  This  stands  in  stark  contrast  to  
the  retrospective  analysis  conducted  by  Machtay  et  al.  in  2008  showing  29  of  230  
patients  requiring  gastrostomy  tubes  two  or  more  years  after  chemoradiation  
(Machtay  et  al.  2008).  The  results  presented  by  Genden  et  al.  also  demonstrate  
an  improvement  above  the  benchmark  noted  by  Givens  et  al.  of  26%  of  patients  
requiring  a  feeding  tube  at  the  one-­year  mark  following  chemoradiation  (Givens  
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et  al.  2009).  In  a  similarly  promising  fashion  as  Genden  et  al.,  Moore  et  al.  
observed  that  of  45  patients  treated  with  TORS,  none  required  a  feeding  tube  at  
the  one-­year  post-­treatment  mark  (Moore,  Olsen,  and  Kasperbauer  2009).  While  
slightly  less  impressive  than  the  functional  results  seen  by  Genden  et  al.  and  
Moore  et  al.,  Iseli  et  al.  noted  only  a  17%  feeding  tube  dependence  1  year  after  
TORS  in  their  cohort  of  54  patients  (Iseli  et  al.  2009).  Mercante  et  al.  conducted  a  
retrospective  review  of  13  patients  treated  with  definitive  TORS  between  2010  
and  2013  for  T1  or  T2  tongue  base  malignancies  and  found  that  no  patient  was  
feeding-­tube-­dependent  for  long  after  treatment;;  the  longest  noted  feeding-­tube  
dependence  was  21  weeks  for  only  1  patient  (Mercante  et  al.  2015).  Mercante  et  
al.  also  compared  their  results  to  the  existing  literature  at  the  time  and  found  
concordance  with  the  widely-­reported  low  post-­TORS  feeding  tube  dependence  
of  around  3%;;  this  statistic  and  the  results  of  their  primary  study  were  seen  to  
differ  strongly  from  the  rates  of  up  to  39%  reported  in  studies  using  primary  
chemoradiation  (Mercante  et  al.  2015).    
  
The  results  reported  by  these  studies  also  showed  promisingly  low  rates  of  post-­
treatment  tracheostomy  that  stand  in  contrast  to  the  results  presented  by  Givens  
et  al.  of  nearly  14%  tracheostomy-­dependence  at  one  year  following  
chemoradiation  (Givens  et  al.  2009).  Genden  et  al.  observed  no  post-­operative  
tracheostomy  tube  placement,  Moore  et  al.  observed  few  patients  with  
tracheostomy  tube  placement  with  all  being  decannulated  within  7  days,  and  Iseli  
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et  al.  observed  9%  tracheostomy  tube  use  post-­TORS  with  universal  
decannulation  within  14  days  of  surgery  (Genden,  Desai,  and  Sung  2009;;  Moore,  
Olsen,  and  Kasperbauer  2009;;  Iseli  et  al.  2009).  These  studies  demonstrate  the  
excellent  functional  outcomes  of  TORS,  particularly  when  compared  with  
chemoradiation  regimens.    
  
QUALITY  OF  LIFE  OUTCOMES  
In  addition  to  quantifiable  functional  outcomes  such  as  gastrostomy  or  
tracheostomy  tube  dependence,  it  is  important  to  value  patients’  self-­reported  
quality  of  life  following  treatment  to  fully  understand  the  ramifications  of  cancer  
treatment.  To  address  this  question,  Genden  et  al.  (2011)  compared  patient-­
reported  scores  on  the  Performance  Status  Scale  for  Head  and  Neck  Patients  
(PSS-­HN),  a  questionnaire  used  to  evaluate  patient  quality  of  life  following  
treatment  for  head  and  neck  malignancies,  for  two  population:  one  that  received  
primary  treatment  with  chemoradiation  and  another  that  received  primary  
treatment  with  TORS  (Genden  et  al.  2011).  As  shown  in  the  following  figure,  the  
researchers  noted  similar  trends  between  the  two  groups  in  several  categories  
related  to  quality  of  life  including  eating,  overall  diet,  and  speech  (Genden  et  al.  
2011).  Genden  et  al.  noted  a  significantly  higher  eating  and  diet  score  on  
average  in  the  TORS  group  compared  to  the  chemoradiation  group  2  weeks  after  
treatment  (Genden  et  al.  2011).  However,  as  visible  in  the  line  graphs  below,  
PSS-­HN  scores  for  both  treatment  groups  with  respect  to  eating,  diet,  and  
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speech  converged  3  months  after  treatment  and  remained  statistically  




Figure  3:  Patient-­reported  quality  of  life  outcomes  following  primary  
chemoradiation  or  TORS.  Mean  PSS-­HN  scores  for  Eating  (A),  Diet  (B),  
Speech  (C),  and  Functional  Oral  Intake  (FOIS;;  D)  across  time  are  shows  for  the  
chemoradiation  group  (red)  and  the  TORS  group  (blue).  Scores  (y-­axis)  range  
from  zero  (minimum)  to  ten  (maximum).  Times  (x-­axis)  range,  from  left  to  right,  
from  Pre-­Treatment  to  Post-­Treatment,  3  month  follow-­up,  6  month  follow-­up,  9  
month  follow-­up,  and  12  month  follow-­up.  Figures  taken  from  (Genden  et  al.  
2011)  via  Wiley  Online  Library.  
  
While  these  results  suggest  that  TORS  yields  quality  of  life  outcomes  at  least  
comparable  to  chemoradiation,  they  do  not  provide  overwhelming  support  for  the  
idea  that  TORS  is  clearly  superior  to  chemoradiation  with  respect  to  functional  
outcomes  and  patient-­reported  quality  of  life.  However,  given  that  83.3%  of  the  
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30-­person  TORS  cohort  in  this  study  received  adjuvant  radiation,  all  patients  
received  IMRT  5.5  weeks  after  surgery,  and  chemotherapy  was  given  to  almost  
half  of  the  patients,  it  is  likely  that  the  results  of  this  study  were  skewed  by  the  
prevalence  of  adjuvant  therapies  (Genden  et  al.  2011).      
  
Studies  that  consider  patient  populations  undergoing  TORS  monotherapy  are  
better  equipped  to  inform  the  scientific  community  about  the  potential  post-­
treatment  quality  of  life  benefits  of  surgery  over  chemoradiation.  In  line  with  this  
idea,  Leonhardt  et  al.  conducted  a  prospective  trial  in  which  38  patients  treated  
with  TORS  with  or  without  adjuvant  therapies  (IMRT  or  chemotherapy  with  IMRT)  
were  administered  the  PSS-­HN  questionnaire  as  well  as  the  SF-­8,  an  8-­question  
survey  designed  to  assess  patient  health-­related  wellbeing  (Leonhardt  et  al.  
2012).  Similar  to  the  results  reported  by  Genden  et  al.  (2011),  the  group  
concluded  that  all  three  groups  (surgery  alone,  surgery  with  IMRT,  and  surgery  
with  IMRT  plus  chemotherapy)  experienced  a  dip  in  quality  of  life  around  the  6  
month  post-­treatment  mark  (Leonhardt  et  al.  2012).  This  decrease  in  quality  of  
life  was  increasingly  more  profound  as  treatment  was  intensified,  with  the  TORS  
plus  chemoradiation  group  showing  worse  outcomes  than  the  TORS  alone  group  
(Leonhardt  et  al.  2012).  An  important  finding  of  this  study  was  that  the  TORS  
alone  group  more  quickly  rebounded  to  pre-­treatment  quality  of  life  baseline  
scores  than  the  groups  treated  with  adjuvant  therapies  (Leonhardt  et  al.  2012).  
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These  results  suggest  that  TORS  alone  places  less  of  a  quality  of  life  burden  on  
patients  than  treatment  regimens  that  include  adjuvant  therapies.    
  
Mercante  et  al.  noticed  a  similar  dip  in  quality  of  life  at  the  6  month  mark  for  
patients  receiving  TORS-­only  treatment,  as  judged  by  patient-­assessed  
swallowing  function  (Mercante  et  al.  2015).  However,  swallowing  function  
recovered  universally  by  the  12  month  mark  for  their  small  cohort  (Mercante  et  al.  
2015).  These  trends  were  mirrored  in  a  quality  of  life  analysis  of  34  patients  
treated  with  TORS  alone  by  Choby  et  al.  (Choby  et  al.  2015).  This  team  noted  
that  patients  recovered  to  pre-­treatment  baseline  in  activity,  chewing,  pain,  and  
swallowing  within  6  months  of  TORS  and  that  this  recovery  endured  through  a  2-­
year  post-­operative  follow-­up  (Choby  et  al.  2015).    
  
The  quality  of  life  benefit  of  TORS  monotherapy  over  strategies  utilizing  adjuvant  
radiation  and/or  chemotherapy  was  also  supported  by  Ling  et  al.  in  2016.  The  
team  reviewed  results  of  a  University  of  Washington  Quality  of  Life  survey  given  
to  a  total  of  138  patients  over  the  course  of  2  years  following  treatment  (Ling  et  
al.  2016).  92  of  these  patients  were  treated  with  TORS  alone  or  with  TORS  plus  
adjuvant  therapy,  and  46  were  treated  with  chemoradiation  alone  (Ling  et  al.  
2016).  Longitudinal  results  for  patient-­reported  quality  of  life  in  saliva-­related  and  
gustation-­related  domains  are  depicted  in  the  following  figure.  
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Figure  4:  Saliva-­related  and  taste-­related  quality  of  life  results  for  patients  
following  chemoradiation,  TORS  with  adjuvant  therapy,  or  TORS  alone.  The  
chemoradiation  group  is  shown  in  blue,  the  TORS  with  adjuvant  therapy  group  in  
red,  and  the  TORS  alone  group  in  green.  Reprinted  from  Oral  Oncology,  Vol.  61,  
Ling  et  al.,  Oncologic  outcomes  and  patient-­reported  quality  of  life  in  patients  with  
oropharyngeal  squamous  cell  carcinoma  treated  with  definitive  transoral  robotic  
surgery  versus  definitive  chemoradiation,  Copyright  2016,  with  permission  from  
Elsevier.  
  
Two  important  trends  can  be  inferred  from  the  data  reported  by  Ling  et  al.  First,  
TORS  alone  offers  substantial  quality  of  life  benefits  over  definitive  
chemoradiotherapy.  This  is  clear  from  the  nearly  30%  higher  mean  scores  in  
saliva-­related  quality  of  life  for  definitive  TORS  patients  over  definitive  
chemoradiotherapy  patients  at  the  1  month  post-­treatment  mark  through  the  2  
year  follow-­up  (Ling  et  al.  2016).  Second,  this  study,  like  the  one  conducted  by  
Leonhardt  et  al.,  suggests  that  the  addition  of  adjuvant  therapy  to  TORS  
treatment  negatively  impacts  quality  of  life  (Ling  et  al.  2016;;  Leonhardt  et  al.  
2012).  This  latter  idea  was  also  supported  by  Al-­khudari  et  al.  In  a  retrospective  
analysis  including  17  patients  who  underwent  TORS  either  with  (n=9)  or  without  
(n=8)  adjuvant  therapies  for  T1-­T2  OPSCC,  the  group  observed  no  feeding  tube  
dependence  in  the  TORS-­alone  group  while  44.4%  of  the  TORS-­with-­adjuvant-­
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therapy  group  required  feeding  tube  use  after  surgery  (Al-­Khudari  et  al.  2013).  
Half  of  these  patients  remained  feeding-­tube-­dependent  at  least  one  year  after  
treatment  (Al-­Khudari  et  al.  2013).  While  the  sample  size  is  limited  in  the  study  
conducted  by  Al-­khudari  et  al.,  the  results  nonetheless  support  the  idea  that  
omitting  adjuvant  therapy  provides  functional  benefits  to  patients  treated  with  
TORS  for  OPSCC  (Al-­Khudari  et  al.  2013).    
  
From  the  aforementioned  studies,  it  is  clear  that  TORS  in  many  cases  offers  
patients  functional  and  quality  of  life  outcomes  superior  to  those  that  would  
presumably  result  from  chemoradiation.  Given  the  fact  that  the  largest  benefit  
over  chemoradiation  in  these  domains  was  observed  in  patients  treated  with  
TORS  alone,  the  question  becomes  if  TORS  as  a  technology  can  help  patients  
avoid  adjuvant  therapies,  either  all  together  or  through  less  aggressive,  reduced-­
dose  regimens.  In  order  to  understand  this  question,  the  emerging  oncologic  data  
related  to  TORS  in  the  treatment  of  OPSCC  must  be  considered.  Given  the  
promising  functional  and  quality  of  life  outcomes  with  TORS,  if  TORS  can  provide  
oncologic  outcomes  similar  to  or  better  than  regimens  with  radiation  and  
chemotherapy,  or  if  the  post-­TORS  patient  can  safely  receive  lower  doses  of  
adjuvant  therapy  without  compromising  their  chances  of  survival,  TORS  is  the  
logical  choice  for  patients  with  OPSCC  (Moore,  Hinni,  et  al.  2012).      
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ONCOLOGIC  OUTCOMES  
Evaluations  of  the  oncologic  outcomes  following  TORS  have  been  promising  
when  compared  to  the  established  figures  for  the  oncologic  golden-­standard  of  
chemoradiation.  In  2010,  White  et  al.  retrospectively  reviewed  the  experiences  of  
surgeons  using  TORS  for  squamous  cell  carcinoma  of  the  head  and  neck  (87%  
of  which  were  OPSCC  cases)  at  the  University  of  Alabama  at  Birmingham  and  
the  Mayo  Clinic  in  Rochester,  MN  (White  et  al.  2010).  89  patients  were  treated  
with  TORS  between  the  two  institutions,  with  71%  of  patients  receiving  adjuvant  
therapy  of  some  kind  due  to  high-­risk  pathological  markers  such  as  the  
involvement  of  multiple  lymph  nodes  or  concerning  surgical  margins  (White  et  al.  
2010).  29%  of  patients  avoided  adjuvant  therapy  all  together  (White  et  al.  2010).  
Across  the  entire  cohort,  a  2-­year  recurrence-­free  survival  rate  of  86.3%  was  
observed  (White  et  al.  2010).  This  matches  closely  with  the  2-­year  oncologic  
control  values  in  the  80-­90%  range  reported  by  other  studies,  such  as  the  
aforementioned  de  Arruda  et  al.  and  Huang  et  al.  studies  (de  Arruda  et  al.  2006;;  
Huang  et  al.  2008).  White  et  al.  also  noted  no  incremental  survival  benefit  of  
radiation  or  chemotherapy  on  top  of  TORS  treatment,  further  supporting  the  
positive  outcomes  associated  with  TORS  treatment  (White  et  al.  2010).  Moore  et  
al.  (2012),  in  their  study  of  66  patients  receiving  TORS  for  OPSCC,  observed  2-­
year  disease-­specific  survival  and  recurrence-­free  survival  rates  of  95.1%  and  
92.4%,  respectively  (Moore  et  al.  2012).  Park  et  al.  also  reported  high  oncologic  
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control  with  TORS,  demonstrating  a  2-­year  overall  survival  rate  of  96%  and  a  
disease-­free  survival  rate  of  92%  in  their  cohort  of  39  (Park  et  al.  2013).    
  
A  multi-­institutional,  retrospective  study  published  by  de  Almieda  et  al.  in  2015  
encapsulates  the  emerging  understanding  of  the  oncologic  control  seen  with  
TORS.  Among  410  patients  treated  with  TORS  (31.3%  also  receiving  adjuvant  
chemotherapy  or  radiotherapy),  the  2-­year  locoregional  control  rate  was  91.8%,  
the  disease-­specific  survival  rate  was  94.5%,  and  the  overall  survival  rate  was  
91%  (de  Almeida  et  al.  2015).  These  numbers,  derived  from  hundreds  of  patients  
treated  with  TORS  in  the  early  21st  century,  support  the  idea  that,  at  least  when  
used  with  adjuvant  treatment,  TORS  provides  excellent  oncologic  outcomes  that  
meet  the  standard  set  by  concurrent  chemoradiation.    
  
Powerful  support  for  the  use  of  TORS  in  OPSCC  treatment  was  presented  by  
Sharma  et  al.  in  2016.  Their  cohort  of  127  patients  treated  for  OPSCC  at  either  
the  University  of  Washington  or  the  University  of  Minnesota  included  two  
populations,  one  treated  with  primary  TORS  (some  with  adjuvant  therapies)  and  
one  treated  with  primary  chemoradiation  (Sharma  et  al.  2016).  In  order  for  
patients  to  be  directly  compared  to  their  counterparts  in  the  other  treatment  
group,  patients  were  matched  by  pathological  stage  (Sharma  et  al.  2016).  
Immediately  following  treatment  and  up  to  72  months  post-­treatment,  no  
significant  difference  in  overall  survival  was  observed  between  the  surgical  and  
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non-­surgical  groups  although  the  survival  rate  in  the  surgical  group  was  higher  
(Sharma  et  al.  2016).  These  results  again  suggest  that  treatment  with  TORS  at  
least  meets  the  oncologic  standard  set  by  chemoradiation.  Together  with  the  
lower  observed  gastrostomy  tube  rate  in  the  surgical  group,  the  encouraging  
survival  rates  with  TORS  reported  by  this  study  strongly  support  the  role  of  
TORS  in  OPSCC  treatment  (Sharma  et  al.  2016).    
  
At  least  one  study  has  investigated  the  effects  of  tumor  HPV  status  on  the  
oncologic  outcomes  following  TORS  treatment.  Cohen  et  al.  retrospectively  
reviewed  50  patients  treated  for  OPSCC  with  TORS  (Cohen  et  al.  2011).  74%  
(n=37)  of  these  patients  had  HPV-­positive  tumors,  91%  of  which  were  HPV-­16-­
positive  (Cohen  et  al.  2011).  82%  of  the  cohort  was  treated  with  adjuvant  therapy  
of  some  sort  including  chemoradiation  with  IMRT  or  IMRT  alone  (Cohen  et  al.  
2011).  Kaplan-­Meier  survival  curves  for  overall  survival,  disease-­specific  survival,  
and  disease-­free  survival  across  the  patient  cohort  are  reproduced  below.  
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Figure  5:  Survival  curves  by  HPV-­status  for  patients  treated  with  TORS.  A)  
Overall  survival,  B)  disease-­specific  survival,  and  C)  disease-­free  survival.  HPV-­
positive  patients  are  shown  in  green,  and  HPV-­negative  patients  are  shown  in  
blue.  No  significant  differences  were  observed  between  the  two  curves  for  any  of  
the  three  parameters  analyzed.  Figure  reprinted  from  (Cohen  et  al.  2011)  via  
Wiley  Online  Library.    
  
No  significant  difference  in  these  three  categories  of  oncological  outcomes  were  
observed  between  the  HPV-­positive  and  HPV-­negative  tumor  groups  (Cohen  et  
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al.  2011).  Indeed,  both  populations  showed  excellent  oncologic  control  across  
these  categories.  These  results  suggest  that  HPV-­positive  tumors  respond  to  
TORS  with  adjuvant  therapy  at  least  as  well  as  HPV-­negative  tumors.  When  
considered  in  conjunction  with  the  studies  previously  mentioned  that  suggest  
HPV-­positive  patients  generally  have  better  oncologic  outcomes  than  their  HPV-­
negative  counterparts,  the  results  of  the  study  conducted  by  Cohen  et  al.  support  
the  role  of  TORS  in  de-­escalated  treatment  regimens  for  this  population  (Ragin  
and  Taioli  2007;;  Ang  et  al.  2010;;  Cohen  et  al.  2011).  
  
Several  studies  have  been  published  that  show  excellent  oncologic  control  in  
patients  with  early-­stage  OPSCC  treated  with  TORS  only.  In  2017,  Dabas  et  al.  
reported  on  their  cohort  of  57  patients  treated  with  TORS  for  early  stage  (T1-­T2)  
OPSCC  (Dabas  et  al.  2017).  Pathology  results  following  surgery  confirmed  T1-­T2  
disease  in  49  of  these  patients,  and  all  of  these  patients  were  spared  subsequent  
chemoradiation  (Dabas  et  al.  2017).  At  29  months  following  TORS,  89.6%  of  
these  patients  were  free  of  recurrent  disease,  and  the  overall  survival  rate  was  
93.8%  (Dabas  et  al.  2017).  While  this  study  was  conducted  with  a  uniformly  
HPV-­negative  patient  population,  it  can  be  inferred  based  on  previously-­
mentioned  research  that  HPV-­positive  individuals  with  early-­stage  OPSCC  would  
show  at  least  the  same  if  not  better  oncologic  outcomes  with  TORS  monotherapy  
(Dabas  et  al.  2017).    
  
	   45	  
Sinha  et  al.  reported  similarly  promising  oncologic  results  even  when  adjuvant  
radiation  following  TORS  for  early-­stage  OPSCC.  The  group  observed  no  
significant  difference  in  local  control  (judged  from  local  recurrence  rate  and  local  
recurrence-­free  survival  rate)  between  the  46%  of  their  202-­patient  population  
that  received  no  post-­operative  irradiation  of  the  primary  tumor  site  and  the  54%  
that  did  (Sinha  et  al.  2016).  The  group  did,  however,  observe  a  34.5%  lower  
temporary  feeding  tube  rate  in  the  group  that  received  no  radiation  (Sinha  et  al.  
2016).  For  patients  with  more  advanced  disease  (T3-­T4),  superior  local  control  
was  in  fact  noted  with  the  addition  of  radiation,  as  were  the  accompanying  higher  
gastronomy  tube  rates  (Sinha  et  al.  2016).  These  results  support  the  use  of  
TORS  monotherapy  in  the  treatment  of  early-­stage  OPSCC  but  caution  that  
TORS  alone  may  not  be  sufficient  for  patients  with  more  advanced  disease.    
  
TORS  AND  TREATMENT  DE-­ESCALATION  
One  of  the  largest  potential  upsides  for  patients  receiving  TORS  is  the  possibility  
of  reduced  adjuvant  therapy.  As  mentioned  above,  it  has  been  demonstrated  that  
as  OPSCC  treatment  regimens  are  escalated  with  chemotherapy,  functional  
outcomes  decline.  This  can  be  concluded  inferentially  from  studies  comparing  
TORS-­only  populations  to  TORS-­with-­adjuvant-­therapy  populations  (e.g.,  Ling  et  
al.  2016),  and  more  directly  through  studies  that  have  observed  dose-­dependent  
functional  outcomes  for  patients  treated  with  chemotherapy  and/or  radiation  for  
OPSCC.  One  such  study,  published  by  Levendag  et  al.  in  2007,  showed  a  19%  
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increase  in  the  probability  of  developing  post-­radiation  dysphagia  with  each  
incremental  10  Gy  (a  measure  of  absorbed  radiation  dose)  administered  to  
important  swallowing  musculature  above  a  threshold  of  60  Gy  (Levendag  et  al.  
2007).  This  finding  is  meaningful  because  not  only  does  it  establish  a  target  dose  
for  de-­escalated  radiation  treatments,  but  also  because  it  stands  in  contrast  to  
previous  studies  treating  OPSCC  with  an  average  dose  of  70  Gy  (de  Arruda  et  al.  
2006).  A  similar  threshold  for  the  induction  of  swallowing  dysfunction  was  seen  
by  Feng  et  al.  This  group  noted  aspiration  during  swallowing  in  patients  who  
received  mean  radiation  doses  above  60  Gy  or  when  more  than  50%  of  the  
volume  of  the  pharyngeal  constrictor  muscles  received  65  Gy  (Feng  et  al.  2007).  
Based  on  this  body  of  research,  it  is  clear  that  there  is  a  quality  of  life  benefit  to  
be  had  for  patients  who  forgo  chemoradiation  or  high  dose  radiation.    
  
Given  the  dose-­related  toxicities  of  radiation  and  the  observed  toxicities  
associated  with  chemoradiation,  an  interest  in  reducing  patient  exposures  to  
these  therapies  has  emerged.  However,  oncologic  control  must  remain  a  priority,  
otherwise  patients  and  caregivers  will  be  forced  to  make  challenging  decisions  
between  general  survival  and  post-­treatment  quality  of  life  (Mirghani  et  al.  2015).  
To  explore  the  potential  of  TORS  to  reduce  postoperative  adjuvant  therapies,  
Cohen  et  al.  leveraged  one  of  the  large  benefits  of  TORS,  operative  tissue  
histopathology,  to  stratify  patients  by  risk  after  surgery  (Cohen  et  al.  2011).  
Patients  in  the  low-­risk  group,  including  those  with  confirmed  early-­stage  disease  
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and  limited  regional  involvement,  received  a  de-­escalated  IMRT  dose  of  60  Gy  
(Cohen  et  al.  2011).  While  results  for  this  subpopulation  specifically  were  not  
reported,  the  excellent  oncologic  results  for  the  entire  patient  cohort  including  this  
subpopulation  adds  modest  support  for  the  idea  that  de-­escalated  adjuvant  
regimens  are  a  reasonable  approach  following  TORS  treatment  in  patients  with  
early  stage  OPSCC  (Cohen  et  al.  2011).    
  
Genden  et  al.  (2011)  also  added  support  to  the  idea  that  TORS  may  allow  
patients  to  defer  adjuvant  chemotherapy  and/or  radiation.  Similar  to  Cohen  et  al.,  
this  group  used  post-­TORS  pathology  results  to  re-­stage  patients  and  dictate  
adjuvant  treatment  (Genden  et  al.  2011).  In  many  cases,  re-­staging  resulted  in  
patients  receiving  less  aggressive  adjuvant  regimens  than  those  they  would  have  
received  if  their  care  plans  were  based  off  of  clinical  markers  instead  of  a  full  
surgical  pathology  assessment.  In  this  cohort  of  30  patients,  73%  of  whom  had  
advanced  disease  (stage  3-­4),  re-­staging  after  surgery  allowed  46%  of  patients  
to  avoid  chemotherapy,  and  the  median  radiation  dose  across  all  patients  was  60  
Gy  (Genden  et  al.  2011).  Without  TORS,  many  of  these  patients  would  have  
received  chemotherapy  and/or  radiation  up  to  72  Gy.  (Genden  et  al.  2011).  The  
oncologic  results  for  patients  treated  with  primary  TORS  in  this  study  support  the  
notion  that  TORS  is  an  effective  therapy  that  may  also  allow  avoidance  of  
potentially-­damaging  chemoradiation.  Specifically,  the  18-­month  overall  survival  
rate  was  estimated  to  be  93%,  and  the  local  control  rate  was  91%  (Genden  et  al.  
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2011).  However,  examining  the  oncologic  results  on  a  more  granular  level  
reveals  a  cautionary  result:  of  the  two  patients  in  the  cohort  who  experienced  
local  disease  recurrence,  neither  received  postoperative  radiation  (Genden  et  al.  
2011).  This  result  suggests  that  more  research  is  necessary  to  more  fully  
understand  the  degree  to  which  adjuvant  therapies  can  be  reduced  after  surgery  
without  compromising  disease  control.    
  
At  least  one  study  has  suggested  that  primary  surgery  may  not,  in  fact,  allow  for  
lower-­dose  adjuvant  treatment.  In  an  analysis  of  18  patients  with  late-­stage  
OPSCC  (T3-­T4)  treated  with  either  primary  chemoradiation  or  surgery  with  
adjuvant  radiation,  Woo  et  al.  noted  that  the  primary  chemoradiation  group  
received  lower  average  radiation  doses  to  the  larynx  and  parotid  glands  (Woo,  
Freeman,  and  Debenham  2017).  Presumably,  these  patients  had  better  
functional  outcomes  with  respect  to  speech  and  deglutition  than  if  they  had  
received  higher  radiation  doses.  While  these  results  serve  as  a  cautionary  
benchmark  for  proponents  of  surgical  management  of  OPSCC,  a  few  key  factors  
limit  extrapolation  from  this  study  into  modern  treatment  of  OPSCC  with  TORS.  
First,  the  patients  in  this  study  were  exclusively  late-­stage  and  high-­risk  (Woo,  
Freeman,  and  Debenham  2017).  It  has  been  previously  shown  that  these  
patients  require  more  aggressive  treatment  to  control  their  disease,  and  therefore  
this  population  should  likely  not  be  the  focus  of  treatment  de-­escalation  efforts  
(Sinha  et  al.  2016).  Furthermore,  the  surgery  used  in  this  study  was  not  
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expressly  TORS  (Woo,  Freeman,  and  Debenham  2017).  Adjuvant  radiotherapy  
in  this  study  was  administered  to  the  entire  surgical  bed;;  with  non-­robotic  surgical  
techniques,  it  is  likely  that  this  tissue  volume  was  much  higher  than  it  would  have  
been  with  minimally-­invasive  TORS  (Woo,  Freeman,  and  Debenham  2017).  
Nonetheless,  these  results  further  support  the  idea  that  additional  research  is  
necessary  to  better  understanding  the  role  of  TORS  in  reducing  patients’  
exposure  to  adjuvant  therapies.      
  
FUTURE  RESEARCH  
The  degree  to  which  adjuvant  treatment  can  be  safely  reduced  for  OPSCC  
patients,  and  the  role  that  TORS  plays  in  this  reduction,  is  an  area  of  active  
research.  Several  studies  are  currently  being  conducted  to  tackle  this  question  
head-­on  by  analyzing  the  oncologic  outcomes  for  patients  treated  for  OPSCC  
with  TORS  and  de-­escalated  chemoradiation  regimens.  One  such  trial,  ECOG  
3311,  is  prospectively  analyzing  the  oncologic  and  functional  outcomes  
associated  with  reduced-­dose  radiotherapy  in  post-­TORS,  HPV-­positive  OPSCC  
patients  (Kelly,  Husain,  and  Burtness  2016).  Surgical  pathology  will  allow  
stratification  of  the  patient  population  into  low-­risk  (negative  surgical  margins  with  
limited  regional  node  involvement),  intermediate-­risk,  and  high-­risk  groups  (Kelly,  
Husain,  and  Burtness  2016).  The  groups  will  receive  no  post-­operative  radiation,  
post-­operative  radiation  at  50-­60  Gy,  and  66  Gy  with  cisplatin-­based  
chemotherapy,  respectively  (Kelly,  Husain,  and  Burtness  2016).  This  study  will  
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help  to  determine  which  populations  can  benefit  from  de-­escalated  regimens  
following  TORS.  Another  important  ongoing  trial  is  the  Mayo  Clinic’s  
NCT01932697  which  is  investigating  the  use  of  post-­TORS  IMRT  at  a  dose  of  36  
Gy  administered  in  small  fractions  (Mirghani  et  al.  2015).  This  study  will  help  to  
understand  the  degree  to  which  post-­TORS  adjuvant  therapies  can  be  safely  and  
effectively  reduced.    
  
Several  ongoing  studies  are  also  evaluating  the  effectiveness  and  safety  of  de-­
escalation  through  non-­surgical  methods.  These  methods  include  reducing  the  
baseline  dose  of  IMRT,  identifying  chemotherapy-­responsive  patients  through  
induction  chemotherapy  and  reducing  subsequent  radiation  doses  in  that  
population,  and  using  antibody-­based  chemotherapy  such  as  cetuximab  in  the  
place  of  traditional  platinum-­based  therapies  like  cisplatin  (Kelly,  Husain,  and  
Burtness  2016).  Another  notable  de-­escalation  strategy  under  current  
investigation  is  the  use  of  therapeutic  vaccines  against  HPV  infection  (Mirghani  
et  al.  2015).  A  study  is  currently  underway  at  the  Johns  Hopkins  Hospital  
(NCT01493154)  to  evaluate  the  effectiveness  of  a  vaccine  given  to  OPSCC  
patients  designed  to  increase  the  immune  system’s  elimination  of  HPV-­infected  
epithelium  (Mirghani  et  al.  2015).  If  effective,  this  vaccine  promises  to  change  the  
landscape  of  treatment  for  individuals  with  HPV-­associated  OPSCC.  The  results  
of  these  studies  will  help  to  better  define  the  treatment  options  for  patients  with  
OPSCC.  In  particular,  the  functional  outcomes  of  novel  non-­surgical  regimens  
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will  provide  a  better  sense  of  whether  or  not  surgery  has  a  place  in  the  treatment  
of  OPSCC  in  the  modern  era.        
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CONCLUSIONS  
 
TORS  has  emerged  in  recent  years  as  a  promising  treatment  option  for  patients  
with  OPSCC.  The  robotic  technology  improves  upon  conventional  surgery,  and  in  
doing  so,  spares  patients  the  invasive  surgical  approaches  of  the  20th  century  
(Hockstein,  Nolan,  O’Malley,  et  al.  2005).  The  literature  reviewed  in  this  thesis  
seem  to  suggest  that  opting  for  TORS  over  treatment  with  chemotherapy  and  
radiation  may  provide  patients  with  superior  functional  and  quality  of  life  
outcomes  without  significantly  affecting  chances  of  leading  a  long,  healthy  life.  
While  additional  research  is  necessary  to  fully  characterize  the  role  of  TORS  in  
the  modern  OPSCC  treatment  landscape,  it  is  clear  that  TORS  has  stimulated  
discourse  in  otolaryngology  about  the  optimal  way  to  treat  patients.  Among  the  
ever-­growing  population  of  patients  with  OPSCC,  a  significant  proportion  of  
whom  in  the  modern  era  of  HPV  are  young  and  otherwise  healthy,  this  discourse  
is  likely  warmly  welcomed.        
  
While  TORS  is  a  promising  technology,  with  proven  effectiveness  and  
unexplored  potential,  it  is  not  appropriate  for  every  patient.  As  suggested  by  
Dabas  et  al.  and  Sinha  et  al,  treatment  with  TORS  alone  appears  to  be  a  safe  
alternative  to  chemoradiation  with  fewer  side  effects  for  patients  with  early-­stage  
disease  (Dabas  et  al.  2017;;  Sinha  et  al.  2016).  TORS  may  also  have  an  
important  role  in  the  management  of  patients  with  more  advanced  disease,  as  
the  ability  to  re-­stage  patients  after  surgery  may  allow  some  of  these  patients  to  
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avoid  high-­dose  adjuvant  regimens  and  their  associated  side  effects  (Cohen  et  
al.  2011;;  Genden  et  al.  2011).  However,  the  degree  to  which  adjuvant  therapies  
can  be  safely  de-­escalated  based  on  pathology  and  clinical  results  is  not  fully  
understood.  Indeed,  it  seems  that  in  some  advanced  cases,  standard  
chemoradiation  treatments  are  warranted  if  disease  control  and  patient  survival  
are  the  primary  clinical  goals  (Sinha  et  al.  2016).    
  
TORS  is  a  relatively  new  technology  in  a  rapidly-­changing  treatment  landscape.  
Studies  such  as  ECOG  3311  will  help  to  establish  guidelines  for  when  the  de-­
escalation  of  adjuvant  regimens  is  safe  and  reasonable  (Kelly,  Husain,  and  
Burtness  2016).  Research  in  non-­surgical  technologies  such  as  HPV  vaccines  
will  help  to  define  the  role  of  surgery  in  the  modern  era.  This  future  research  and  
development  will  help  physicians  make  more  informed  clinical  decisions  and  will  
ultimately  lead  to  patients  leading  longer  lives  free  of  debilitating  treatment  side-­
effects.  
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